|
Laxman Pai, Opalesque Asia: Healthcare-focused investment firm OrbiMed has raised over $4.3 billion across three new funds to invest in public and private biotechs amid a lengthy market downturn.
New York-based OrbiMed said in a media release that it raised just more than $1.86 billion for its ninth venture-capital vehicle, OrbiMed Private Investments IX, $1.71 billion for its fourth royalties and credit pool, OrbiMed Royalty & Credit Opportunities IV, and a $751 million Asia fund, OrbiMed Asia Partners V, its fifth fund focused on the region.
"Consistent with their predecessors, these new funds enable OrbiMed to invest globally, from seed stage for start-ups incubated by OrbiMed through growth capital opportunities," the release said.
OrbiMed works closely with its portfolio companies to provide tailored financing solutions, which can include equity, credit, and royalty-based financing. OrbiMed focuses on innovative and growth-oriented opportunities across healthcare sub-sectors, including biopharmaceuticals, medical devices, diagnostics, and technology-enabled healthcare services.
According to the release, OrbiMed is led by its 21 partners, with a growing team exceeding 130 professionals that contribute diverse, complementary skills across company incubation, strategy, operations, and finance. The firm's professionals are based in a dozen global locations across key healthcare markets in North America, Europe and Asia.
Investors in these new funds inc...................... To view our full article Click here
|
RSS
